Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Revenue: 2010-2025

Historic Revenue for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to $115.5 million.

  • Ligand Pharmaceuticals' Revenue rose 122.85% to $115.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.2 million, marking a year-over-year increase of 64.83%. This contributed to the annual value of $167.1 million for FY2024, which is 27.28% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Revenue of $115.5 million as of Q3 2025, which was up 142.43% from $47.6 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Revenue ranged from a high of $115.5 million in Q3 2025 and a low of $26.4 million during Q2 2023.
  • In the last 3 years, Ligand Pharmaceuticals' Revenue had a median value of $42.8 million in 2024 and averaged $46.1 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Revenue slumped by 47.40% in 2023, and later spiked by 122.85% in 2025.
  • Quarterly analysis of 5 years shows Ligand Pharmaceuticals' Revenue stood at $56.4 million in 2021, then fell by 10.68% to $50.4 million in 2022, then crashed by 44.22% to $28.1 million in 2023, then surged by 52.35% to $42.8 million in 2024, then surged by 122.85% to $115.5 million in 2025.
  • Its last three reported values are $115.5 million in Q3 2025, $47.6 million for Q2 2025, and $45.3 million during Q1 2025.